Fondaparinux for Management of Heparin-induced Thrombocytopenia after Cardiovascular Intervention: A systematic review
| Autor: | Vijaya Raj Bhatt, Vivek Verma, Ranjan Pathak, Smith Giri, Sumit Dahal, Prem Shukla, Nabin Khanal |
|---|---|
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment MEDLINE Renal function Fondaparinux Valve replacement Polysaccharides Internal medicine Heparin-induced thrombocytopenia medicine Humans Cardiac Surgical Procedures Pharmacology Heparin business.industry Anticoagulants Hematology medicine.disease Thrombocytopenia Thrombosis Surgery Cardiac surgery Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Scopus-Elsevier |
| Popis: | OBJECTIVES The efficacy and safety of fondaparinux, an emerging therapeutic option for heparin-induced thrombocytopenia (HIT), remain unclear in cardiac surgery patients with HIT. METHODS Using several search criteria, we reviewed all cases of fondaparinux use in patients who developed HIT after any cardiovascular intervention and were indexed in MEDLINE by August 2014. Based on pre-specified criteria, cases were divided into confirmed HIT, probable HIT and possible HIT. The outcome of fondaparinux use in each group was compared using Chi-square test. RESULTS Of 43 total cases, 22 had confirmed HIT and 21 had possible HIT. Valve replacement or repair (39%) and heart transplant or ventricular assist device placement (21%) were the most common preceding cardiovascular interventions. Creatinine clearance |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|